Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Palantir Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Palantir Technologies Inc trades at $127.63 (market cap $303.96B). The key difference: Palantir Technologies Inc is far larger — about 7.6× Alnylam Pharmaceuticals, Inc.'s market cap. Which is the better fit depends on your goals.
| ALNY | PLTR | |
|---|---|---|
Market Cap | $39.89B | $303.96B |
Sector | Health | Technology |
52-Week High | $491.22 | $207.18 |
52-Week Low | $278.09 | $107.27 |
Enterprise Value | $38.15B | $296.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PLTR trades at $126.79, down 1.74% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong fundamentals, with Q1 2026 EPS of $0.33 beating expectations, revenue growth accelerating to 85% YoY, and a net income margin of 43.67%. Recent news highlights CEO commentary on AI competition and robust U.S. revenue expansion of 104%.
The outlook remains positive given earnings beats and growth trajectory, but high valuation multiples (P/E 142.46) pose a risk if growth slows. Analyst consensus price target is $185.67, suggesting upside, though bearish technicals and sector volatility warrant caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
